# Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)

> **NCT05101122** · PHASE1,PHASE2 · COMPLETED · sponsor: **Apnimed** · enrollment: 15 (actual)

## Conditions studied

- Obstructive Sleep Apnea

## Interventions

- **DRUG:** Dosing 1: Atomoxetine
- **DRUG:** AD313

## Key facts

- **NCT ID:** NCT05101122
- **Lead sponsor:** Apnimed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-19
- **Primary completion:** 2022-04-18
- **Final completion:** 2022-04-18
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05101122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05101122, "Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05101122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*